Form 4: Corcept Executive Sean Maduck Executes Stock Transactions

Corcept Therapeutics President Sean Maduck exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• President Sean Maduck exercised options to acquire 25,000 shares of Corcept Therapeutics common stock at $8.27 per share.
• Following the exercise, the reporting person sold 25,000 shares in two tranches at weighted average prices of $70.1068 and $70.7462.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
• The reporting person also acquired 1,230 shares through a company purchase plan and restricted stock awards.
• 452 shares were withheld by the company to satisfy tax obligations related to restricted stock unit vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing reflecting standard executive compensation and liquidity management.

Positives

• The executive maintains a significant indirect beneficial ownership stake in the company through various trusts and LLCs, totaling over 115,000 shares.
• The exercise of options and subsequent sales were conducted under a pre-established 10b5-1 plan, indicating a structured approach to liquidity rather than reactive trading.

Negatives

• The transaction resulted in a net reduction of direct common stock holdings by the reporting person.

Risks

• Future share price volatility could impact the value of the remaining 9,755 shares held directly and the various indirect holdings.
• Reliance on 10b5-1 plans does not eliminate market risk for the executive's remaining equity position.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The filing notes that the transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy Rule 10b5-1(c) conditions.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to manage personal wealth and tax obligations, and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of 10b5-1 plans is consistent with best practices for corporate governance among U.S. publicly traded biotechnology companies.
• The volume of shares sold relative to the executive's total holdings is typical for periodic liquidity events.

Corporate Governance

Stakeholder Impact

• Shareholders should view this as a routine transaction by an executive, not indicative of a change in company outlook.

Next Steps

• Vesting of remaining restricted stock awards on their respective one-year anniversaries.

Key Dates

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, 10b5-1 Plan